Dr. Nathaniel S. Winstead, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 411
Licensed in Alabama since 2004, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AL license 25945 (first issued 2004; active) · LA license MD.025020
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mobile Infirmary Medical Center Mobile, AL
- Thomas Hospital Fairhope, AL
Medical groups
- Imc-Gulf Coast Gastroenterology LLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 411
- Services billed
- 774
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | 96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 100 | 98 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 92 | 85 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 69 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 63 | 48 |
| Biopsy of large bowel using a flexible endoscope | 52 | 52 |
| Diagnostic exam of large bowel using a flexible endoscope | 45 | 45 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 41 | 40 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 26 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 26 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Fairhope, AL | 294 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 92 |
| Esomeprazole Magnesium Other prescribers in Fairhope, AL | 80 |
| Pantoprazole Sodium Other prescribers in Fairhope, AL | 78 |
| Sutab (sod sulf/pot chloride/mag sulf) | 44 |
| Omeprazole Other prescribers in Fairhope, AL | 30 |
| Sucralfate Other prescribers in Fairhope, AL | 23 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Fairhope, AL | 20 |
| Methylprednisolone Sodium Succ (methylprednisolone sod succ) | 13 |
| Remicade (infliximab) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 23 payments worth $482 in total to this clinician.
| AbbVie Inc. | $157 |
|---|---|
| Pfizer Inc. | $101 |
| Dilon Technologies, Inc. | $56.08 |
| Olympus America Inc. | $49.74 |
| Conmed Corporation | $45.99 |
| Phathom Pharmaceuticals, Inc. | $33.81 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.31 |
| Janssen Biotech, Inc. | $17.28 |
| Food and Beverage | $482 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $4,236 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Sanofi US Services Inc. · Active, not recruiting · NCT06975722 - Vixarelimab ulcerative colitis study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.